POLIO [to 14 January 2017]

POLIO [to 14 January 2017]
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 11 January 2017
:: Summary of newly-reported viruses this week (see country-specific section below for further details): Pakistan: one circulating vaccine-derived poliovirus type 2 (cVDPV2) isolated from an acute flaccid paralysis (AFP) case; three positive environmental samples (two wild poliovirus type 1 – WPV1, and one cVDPV2).

Country Updates [Selected Excerpts]
Pakistan
:: Two new WPV1-positive environmental samples were reported in the past week, from Multan, Punjab (collected on 8 December) and Karachi-Landhi (greater Karachi), Sindh (collected on 14 December).
:: One new circulating vaccine-derived poliovirus type 2 (cVDPV2) case was reported in the past week, from Quetta, Balochistan, with onset of paralysis on 17 December.
:: One new cVDPV2-positive environmental sample was reported in the past week, from Quetta (collected on 20 December).
:: The isolates from both the cVDPV2 case and environmental sample are linked to an ongoing, confirmed cVDPV2 outbreak currently affecting Quetta. The case is the first associated with this outbreak – previous isolates of this strain had been found only in environmental samples.
:: An outbreak response is currently ongoing. Last week, a campaign using monovalent oral polio vaccine type 2 (mOPV2) was implemented in Quetta and surrounding areas, followed this week by an activity with inactivated polio vaccine (IPV). The Ministry of Health, supported by the World Health Organization (WHO) and partners, is further strengthening active search for cases of acute flaccid paralysis (AFP), and conducting an in-depth field investigation to more clearly ascertain the extent of circulation of the cVDPV2.

::::::

WHO & Regional Offices

WHO & Regional Offices [to 14 January 2017]

140th session of the Executive Board
23 January–1 February 2017, Geneva
[see selected main documents summary above]

Tobacco control can save billions of dollars and millions of lives
10 January 2017 – Policies to control tobacco use, including tobacco tax and price increases, can generate significant government revenues for health and development work, according to a new landmark global report from WHO and the National Cancer Institute of the United States of America.

Highlights
Dracunculiasis eradication: Mali reports zero cases in 2016
January 2017 – In 2016, a total of 25 human cases of dracunculiasis (guinea-worm disease) were reported to WHO; Mali reported zero cases for the first time. In 2015, Mali reported 5 human cases.

Consultation: Global Accelerated Action for the Health of Adolescents (AA-HA!) Implementation Guidance Draft
January 2017 – The first draft of the Global AA-HA! Implementation Guidance is now available for review by individuals and institutions. If you have feedback, please respond by 15th January 2017 so that your comments can influence and be incorporated into the final document.

Response to trauma cases saves hundreds of lives in Iraq
January 2017 – Since 17 October 2016, WHO has supported the Government of Iraq and the Kurdish Regional Government with emergency lifesaving health services, including emergency medicines and other medical supplies like trauma and surgery kits.

Weekly Epidemiological Record, 13 January 2017, vol. 92, 2 (pp. 13–20)
Global Advisory Committee on Vaccine Safety, 30 November – 1 December 2016

:: WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region AFRO
:: Millions of children to receive measles vaccine in north-eastern Nigeria
A mass vaccination campaign to protect more than 4 million children (4 766 214) against a measles outbreak in conflict-affected states in north-eastern Nigeria is planned to start this week.

WHO Region of the Americas PAHO
:: Tobacco control can save billions of dollars and millions of lives (01/10/2017)

WHO South-East Asia Region SEARO
:: Countries in South-East Asia Region combat polio vaccine shortage, committed to remain polio-free 13 January 2017
On the sixth anniversary of the last case of wild poliovirus in the South-East Asia Region, World Health Organization commends countries in the Region for their continued efforts to protect children against this crippling virus and maintain the Region’s polio-free status, despite challenging conditions.
Amid a global shortage of injectable inactivated polio vaccine (IPV), countries in the WHO South-East Asia Region are opting to use fractional doses of IPV, an evidence-based intervention that not only ensures continued protection of children against all types of polioviruses, but also helps save vaccine – a move bound to positively impact global vaccine supply in the coming years.
India became the first country globally to introduce fractional doses of IPV in childhood immunization programme in eight of its 36 states / union territories in early 2016. The initiative is now being scaled up nationwide. Sri Lanka followed suit in July 2016. Bangladesh has decided to introduce fractional IPV doses this year. Other countries in the Region are also considering a shift to the use of fractional IPV doses in their immunization schedule…

WHO European Region EURO
:: Kick-off meeting of UN European coalition on health identifies 4 workstreams for joint action 13-01-2017
:: What can countries expect during the 2016–2017 influenza season? 13-01-2017

WHO Eastern Mediterranean Region EMRO
:: Survey raises concerns about hepatitis C infection in Syria 10 January 2017

WHO Western Pacific Region
:: Tobacco control can save billions of dollars and millions of lives 10 JANUARY 2017

::::::

CDC/ACIP [to 14 January 2017]

CDC/ACIP [to 14 January 2017]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/

MMWR Weekly January 13, 2017/No. 1
[Excerpts]
:: State Laws Requiring Hand Sanitation Stations at Animal Contact Exhibits—United States, March–April 2016
:: Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States

Register for upcoming February ACIP meeting
February 22-23, 2017
Deadline for registration:
:: Non-US Citizens: February 1, 2017; US Citizens: February 13, 2017
Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Announcements

Announcements

IVI [to 14 January 2017]
http://www.ivi.int/

[Undated]
IVI, Rotary International Join Forces to Vaccinate against Cholera in At-risk Populations in Nepal
:: Campaign to vaccinate about 27,000 people to prevent endemic cholera
:: IVI Director General commends Rotary’s leadership and support, announces intent to provide additional vaccinations in developing countries through international collaboration

The International Vaccine Institute (IVI), Rotary International (District 3640, District 3710), Rotary Club of Seoul Southwest in Korea, and Rotary Club of Nagarjun in Nepal announced on January 9 their global health partnership that recently completed vaccination of about 27,000 people at risk of cholera in Nepal.

The vaccinations have been conducted in Banke, an area in southwest Nepal that borders with India, to protect people against cholera, a potentially fatal and highly contagious diarrheal disease. Cholera is endemic in Nepal, and people in the area are at high risk of cholera due to lack of clean water and limited sanitation and hygiene.

The vaccination campaign used a two-dose oral cholera vaccine, developed by IVI through a public-private partnership with groups that include the Bill & Melinda Gates Foundation and the governments of Korea and Sweden. Notably, the vaccine ‘Euvichol’ is produced by the Korean vaccine manufacturer EuBiologics who worked with IVI on its development and production following technology transfer from IVI. The vaccine is prequalified by the World Health Organization and is the first Korean-made cholera vaccine for global public health.

To ensure the vaccine reaches vulnerable populations, IVI collaborated with Rotary International and Nepalese health authorities to conduct the vaccination campaign, targeting residents one year old and up.  The first round occurred on early December, and the second round in mid- to late December.

The vaccination campaign was led by Rotary Club of Seoul Southwest and International Rotary Districts 3640 and 3710, and was supported through a Global Grant from the Rotary Foundation. Collaborators in Nepal included the Nepalese Ministry of Health, Group for Technical Assistance (GTA), and other partners. The campaign was also supported by a number of Korean donors, including the Export Import Bank of Korea, the Kim & Chang CSR Committee, and Sartorius Korea Biotech…

PATH [to 14 January 2017]

PATH [to 14 January 2017]
http://www.path.org/news/index.php

Announcement | January 12, 2017
PATH welcomes grant to advance Group B Streptococcus vaccine development
Award from the Bill & Melinda Gates Foundation will support maternal immunization strategies
PATH has received a five-year, $29.3 million grant from the Bill & Melinda Gates Foundation to support the development of a vaccine against Group B Streptococcus (GBS), a leading cause of sepsis and meningitis in young infants worldwide. A vaccine to prevent the bacterial infection—which often affects babies just a few hours old—could potentially save countless lives in the low-resource countries most impacted by the disease. Grant funds will support the research and development of a polyvalent, conjugate vaccine protecting against the most common kinds (or serotypes) of GBS…

European Medicines Agency [to 14 January 2017]

European Medicines Agency [to 14 January 2017]
http://www.ema.europa.eu/
13/01/2017

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9-12 January 2017
At its monthly meeting, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) discussed two ongoing safety reviews.
More information on all safety reviews currently under evaluation is provided in the table below. The Committee did not start or conclude a referral.
The PRAC also focused on the broad range of its responsibilities which cover all aspects of the risk management of the use of medicines. Information on all topics discussed by the PRAC is available below in the agenda for the meeting. A record of the discussions held this week will be provided in the minutes of this meeting, which will be published following the next PRAC meeting at the beginning of February…

European Vaccine Initiative [to 14 January 2017]

European Vaccine Initiative [to 14 January 2017]
http://www.euvaccine.eu/news-events
09 January 2017

EVI welcomes a new member to the team
EVI extends a warm welcome to María del Mar Castro. Ms del Mar Castro joins EVI with a fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/ Tropical Diseases Research-World Health Organization (TDR/WHO). She began her one-year Clinical Research and Development fellowship on 09 January 2017.

09 January 2017
A new paper related to the MVVC project has recently been published in Molecular Therapy
The article “Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants” was published by Carly Bliss et al. in Molecular Therapy.

::::::

Industry Watch [to 14 January 2017]

Industry Watch [to 14 January 2017]
:: Joaquin Duato Named PhRMA Board Chairman
Washington, DC (January 9, 2017) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson, has been named chairman of PhRMA’s board of directors. Duato formerly held the position of chairman-elect of the PhRMA board and succeeds George Scangos, who has stepped down as CEO of Biogen…

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Tropical Medicine and Hygiene – January 2017; 96 (1)

American Journal of Tropical Medicine and Hygiene
January 2017; 96 (1)
http://www.ajtmh.org/content/current

Editorials
Evidence-Based Policies on Migration and Global Health are Essential to Maintain the Health of Those Inside and Outside the United States
Philip J. Rosenthal, Daniel G. Bausch, Stephen Higgs, N. Regina Rabinovich, David R. Hill, Christopher V. Plowe, Karen A. Goraleski, and Patricia F. Walker
Am J Trop Med Hyg 2017 96:5-6; doi:10.4269/ajtmh.961ed

Excerpt
…In addition to maintaining a humane and evidence-based U.S. policy on migration, we must continue to engage and invest in programs that improve the health of vulnerable populations worldwide. Reaching out to enhance the well-being of those whose lives has been torn apart by war and oppression should be a fundamental and perhaps defining American principle. Programs for populations in need around the world should not be considered antiquated historical notions or reflective of an outmoded inscription on the Statue of Liberty. Indeed, U.S. government leaders from both sides of the political aisle have championed programs aimed at global health, including the creation of the Peace Corps by President John F. Kennedy in 1961, and the President’s Emergency Plan for AIDS Relief and President’s Malaria Initiative by President George W. Bush in 2003 and 2005, respectively. Additional efforts have been shared with other developed countries, notably the Global Fund to Fight AIDS, Tuberculosis, and Malaria. These well-managed programs have offered enormous benefits to the citizens of the developing world, but they have also directly benefitted the United States, by helping to control some of the most important infectious diseases that threaten all of us, by building diplomatic bridges of good will with populations around the world, and by exemplifying the best of American values of kindness and compassion…

BMC Infectious Diseases

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 14 January 2017)

Research article
Mumps transmission in social networks: a cohort study
Mumps emerged among highly vaccinated populations in the Netherlands. This offered a unique opportunity to study mumps virus transmission. In particular the extent to which asymptomatic infections in vaccinate…
Susan Hahné, Tessa Schurink, Jacco Wallinga, Jeroen Kerkhof, Marianne van der Sande, Rob van Binnendijk and Hester de Melker
BMC Infectious Diseases 2017 17:56
Published on: 10 January 2017

Research article
Seasonal influenza vaccination in pregnant women: knowledge, attitudes, and behaviors in Italy
The aims of this study were to assess the knowledge, attitudes, and behaviors towards seasonal influenza and its vaccination among pregnant women.
Francesco Napolitano, Paola Napolitano and Italo Francesco Angelillo
BMC Infectious Diseases 2017 17:48
Published on: 9 January 2017

BMC Public Health

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 14 January 2017)

Research article
An audit of the quality of online immunisation information available to Australian parents
The Internet is increasingly a source of health information for parents, who use the Internet alongside health care providers for immunisation information. Concerns have been raised about the reliability of on…
K. E. Wiley, M. Steffens, N. Berry and J. Leask
BMC Public Health 2017 17:76
Published on: 13 January 2017

The European Journal of Public Health – Volume 26, Issue 6, 1 December 2016

The European Journal of Public Health
Volume 26, Issue 6, 1 December 2016
http://eurpub.oxfordjournals.org/content/26/6

Editorials
Lonely and bored stiff: challenging phase for ethnic minority and migrant health in Europe Restricted Access
Charles Agyemang Eur J Public Health (2016) 26 (6): 898-899 DOI: http://dx.doi.org/10.1093/eurpub/ckw112 First published online: 13 October 2016 (2 pages)

Viewpoint
Environmental and public health tracking to advance knowledge for planetary health
Behrooz Behbod, Paolo Lauriola, Giovanni Leonardi, Helen Crabbe, Rebecca Close, Brigit Staatsen, Lisbeth E. Knudsen, Kees de Hoogh, Sylvia Medina, Jan C. Semenza, Tony Fletcher Eur J Public Health (2016) 26 (6): 900 DOI: http://dx.doi.org/10.1093/eurpub/ckw176 First published online: 15 October 2016 (1 pages)

Infectious Diseases of Poverty

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 14 January 2017]

Research Article
Domestic trends in malaria research and development in China and its global influence
Yang-Mu Huang, Lu-Wen Shi, Rui She, Jing Bai, Shi-Yong Jiao and Yan Guo
Published on: 10 January 2017
Abstract
Background
Though many countries, including China, are moving towards malaria elimination, malaria remains a major global health threat. Due to the spread of antimalarial drug resistance and the need for innovative medical products during the elimination phase, further research and development (R&D) of innovative tools in both epidemic and elimination areas is needed. This study aims to identify the trends and gaps in malaria R&D in China, and aims to offer suggestions on how China can be more effectively involved in global malaria R&D.
Methods
Quantitative analysis was carried out by collecting data on Chinese malaria-related research programmes between 1985 and 2014, invention patents in China from 1985 to 2014, and articles published by Chinese researchers in PubMed and Chinese databases from 2005 to 2014. All data were screened and extracted for numerical analysis and were categorized into basic sciences, drug/drug resistance, immunology/vaccines, or diagnostics/detection for chronological and subgroup comparisons.
Results
The number of malaria R&D activities have shown a trend of increase during the past 30 years, however these activities have fluctuated within the past few years. During the past 10 years, R&D on drug/drug resistance accounted for the highest percentages of research programmes (32.4%), articles (55.0% in PubMed and 50.6% in Chinese databases) and patents (45.5%). However, these R&D activities were mainly related to artemisinin. R&D on immunology/vaccines has been a continuous interest for China’s public entities, but the focus remains on basic science. R&D in the area of high-efficiency diagnostics has been rarely seen or reported in China.
Conclusions
China has long been devoted to malaria R&D in multiple areas, including drugs, drug resistance, immunology and vaccines. R&D on diagnostics has received significantly less attention, however, it should also be an area where China can make a contribution. More focus on malaria R&D is needed, especially in the area of diagnostics, if China would like to contribute in a more significant way to global malaria control and elimination.

JAMA – January 10, 2017, Vol 317, No. 2, Pages 103-222

JAMA
January 10, 2017, Vol 317, No. 2, Pages 103-222
http://jama.jamanetwork.com/issue.aspx

Viewpoint
Revised CIOMS International Ethical Guidelines for Health-Related Research Involving Humans
Johannes J. M. van Delden, MD, PhD; Rieke van der Graaf, PhD
JAMA. 2017;317(2):135-136. doi:10.1001/jama.2016.18977
Abstract
The Council for International Organizations of Medical Sciences (CIOMS) was established jointly by the World Health Organization (WHO) and the United Nations Educational, Scientific and Cultural Organization (UNESCO) in 1949 as an international, nongovernmental, nonprofit organization and now includes 45 international, national, and associate member organizations, representing many of the biomedical disciplines, national academies of sciences, and medical research councils. CIOMS recently released a new version of its International Ethical Guidelines for Health-Related Research Involving Humans. These guidelines were developed in collaboration with WHO and based on authoritative ethical guidance documents, such as the World Medical Association’s Declaration of Helsinki and UNESCO’s Universal Declaration on Bioethics and Human Rights. The aim of the guidelines is to provide internationally vetted ethical principles and detailed commentary on how these principles should be applied, with particular attention to conducting research in low- and middle-income countries (LMICs).

Journal of Travel Medicine – Volume 24, Issue 1, January 2017

Journal of Travel Medicine
Volume 24, Issue 1, January 2017
http://jtm.oxfordjournals.org/content/24/1

Original Article
Pre-travel advice, attitudes and hepatitis A and B vaccination rates among travellers from seven countries
Anita E. Heywood, Hans Nothdurft, Dominique Tessier, Melissa Moodley, Lars Rombo, Cinzia Marano, Laurence De Moerlooze J Travel Med (2017) 24 (1): taw069 DOI: http://dx.doi.org/10.1093/jtm/taw069 First published online: 13 October 2016 (8 pages)

Editor’s Choice
Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet
Sara M. Lammert, Sowmya R. Rao, Emily S. Jentes, Jessica K. Fairley, Stefanie Erskine, Allison T. Walker, Stefan H. Hagmann, Mark J. Sotir, Edward T. Ryan, Regina C. LaRocque J Travel Med (2017) 24 (1): taw075 DOI: http://dx.doi.org/10.1093/jtm/taw075 First published online: 30 October 2016 (7 pages)

Journal of Virology – January 2017, volume 91, issue 2

Journal of Virology
January 2017, volume 91, issue 2
http://jvi.asm.org/content/current

Vaccines and Antiviral Agents
One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus
Christoph Wirblich, Christopher M. Coleman, Drishya Kurup, Tara S. Abraham, John G. Bernbaum, Peter B. Jahrling, Lisa E. Hensley, Reed F. Johnson, Matthew B. Frieman, and Matthias J. Schnell
J. Virol. January 2017 91:e02040-16; Accepted manuscript posted online 2 November 2016 , doi:10.1128/JVI.02040-16
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic respiratory virus. There are no treatment options against MERS-CoV for humans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly reduced viral titers compared to those of the parental RABV strain and only low-level incorporation of full-length MERS-CoV S into RABV particles. Therefore, we developed a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminus (BNSP333-S1). BNSP333-S1 grew to titers similar to those of the parental vaccine vector BNSP333, and the RABV G–MERS-CoV S1 fusion protein was efficiently expressed and incorporated into RABV particles. When we vaccinated mice, chemically inactivated BNSP333-S1 induced high-titer neutralizing antibodies. Next, we challenged both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyzed the ability of mice to control MERS-CoV infection. Our results demonstrated that vaccinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those in unvaccinated controls. These data establish that an inactivated RABV-MERS S-based vaccine may be effective for use in animals and humans in areas where MERS-CoV is endemic.
IMPORTANCE Rabies virus-based vectors have been proven to be efficient dual vaccines against rabies and emergent infectious diseases such as Ebola virus. Here we show that inactivated rabies virus particles containing the MERS-CoV S1 protein induce potent immune responses against MERS-CoV and RABV. This novel vaccine is easy to produce and may be useful to protect target animals, such as camels, as well as humans from deadly MERS-CoV and RABV infections. Our results indicate that this vaccine approach can prevent disease, and the RABV-based vaccine platform may be a valuable tool for timely vaccine development against emerging infectious diseases.

The Milbank Quarterly A Multidisciplinary Journal of Population Health and Health Policy December 2016 Volume 94, Issue 4 Pages 695–928

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
December 2016 Volume 94, Issue 4 Pages 695–928
http://onlinelibrary.wiley.com/doi/10.1111/milq.2016.94.issue-4/issuetoc

Op-Eds
A Very Long Journey: A Decade’s Quest for Quarantine Regulations (pages 724–728)
LAWRENCE O. GOSTIN
Version of Record online: 19 DEC 2016 | DOI: 10.1111/1468-0009.12226

Review Article
Instruments Measuring Integrated Care: A Systematic Review of Measurement Properties (pages 862–917)
MARY ANN C. BAUTISTA, MILAWATY NURJONO, YEE WEI LIM, EZRA DESSERS and HUBERTUS JM VRIJHOEF
Version of Record online: 19 DEC 2016 | DOI: 10.1111/1468-0009.12233
Abstract
Policy Points:
:: Investigations on systematic methodologies for measuring integrated care should coincide with the growing interest in this field of research.
:: A systematic review of instruments provides insights into integrated care measurement, including setting the research agenda for validating available instruments and informing the decision to develop new ones.
:: This study is the first systematic review of instruments measuring integrated care with an evidence synthesis of the measurement properties.
:: We found 209 index instruments measuring different constructs related to integrated care; the strength of evidence on the adequacy of the majority of their measurement properties remained largely unassessed

New England Journal of Medicine – January 12, 2017  Vol. 376 No. 2

New England Journal of Medicine
January 12, 2017  Vol. 376 No. 2
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Eliminating Cholera Transmission in Haiti
Louise C. Ivers, M.D., M.P.H.
N Engl J Med 2017; 376:101-103 January 12, 2017 DOI: 10.1056/NEJMp1614104
Interview with Dr. Louise Ivers on cholera transmission and vaccination efforts in post-hurricane Haiti. (6:48) Listen Download
When Hurricane Matthew struck on October 4, 2016, it left 1.4 million people in southern Haiti in need of urgent humanitarian assistance; it destroyed homes and health care facilities, flooded water sources with runoff, ruined crops, killed livestock, and displaced hundreds of thousands of people. Looming as the next act in the disaster is a resurgence in endemic cholera.

Cholera had not been recorded in Haiti until it was introduced in 2010. The introduction of Vibrio cholerae into a population that had never been exposed to cholera and that had extremely limited access to safe water and sanitation had a predictable effect: an explosive cholera epidemic that has killed at least 10,000 people and caused nearly 800,000 reported cases throughout the country.1

Now in its seventh year, the epidemic has taken an immeasurable toll on individuals, communities, and the health system in Haiti, and the resources for controlling it have been too limited. In 2015, Haiti reported more cases of cholera per population than any other country. In 2016, there were 29,000 cases of cholera in the first 9 months of the year — already a disaster before the hurricane hit. And as is so often the case, the poor have suffered the most. New approaches are needed to address the ongoing problem and mitigate suffering from cholera in Haiti. The hurricane’s aftermath adds urgency to this problem.

On October 13 and 14, 2016, the minister of health and population of Haiti, Daphnee Benoit, convened an expert panel at the U.S. National Institutes of Health to consult on the control of cholera in Haiti with specific reference to the use of vaccines in the aftermath of Hurricane Matthew. Two weeks after Hurricane Matthew, the number of cholera cases had grown, and many were concerned about the impact on human life. The consultation resulted in the following consensus.

The response to Hurricane Matthew must first and foremost address the victims’ need for humanitarian relief, through provision of food, shelter, and clean water to those who lack these lifesaving essentials. Rallying emergency clean-water activities to combat the known risk of cholera in the immediate phase is an important strategy. We should assume, at least initially, that there has been further contamination of freshwater sources in Haiti’s southern peninsula. Ensuring that people have access to and use effectively chlorinated water, with safe water storage at home (or in shelters), is a critical lifesaving objective.

There is a simultaneous need to ensure that cholera treatment centers and oral rehydration posts are functional. After the hurricane, many of these facilities will have to be rebuilt; resupplied with rehydration fluids, antibiotics, and zinc for children; and supported with staff to perform effective case finding in the community and rapid treatment of the sick. These strategies have not changed since the beginning of the cholera epidemic in 2010, although in recent years resources to implement them have dwindled.

When the cholera epidemic began in Haiti, and for some years afterward, there was a lack of consensus on the role that oral cholera vaccine (OCV) could play in the response. One clear issue, however, was that the supply of vaccine was very limited, and there was limited experience in using OCVs in response to outbreaks. Furthermore, the fact that the most affordable vaccine had not yet met prequalification requirements of the World Health Organization (WHO) meant that the United Nations Children’s Fund (UNICEF) and other United Nations agencies could not purchase it.

Since that time, a number of developments have enhanced our ability to control the epidemic in Haiti. Two safe, effective OCVs are now available at an affordable cost ($1.70 to $1.85 per dose), are prequalified by the WHO, and are available in increasing quantities. The products are essentially the same vaccine, made by different manufacturers. Shanchol (Shantha Biotechnics, India) was prequalified in 2011. In 2013, a 2-million-dose OCV stockpile was established as a public good to manage the vaccine. Euvichol (Eubiologics, South Korea) was prequalified by the WHO in 2015, and the manufacturer recently announced that it could produce 25 million single-dose vials per year that remain stable at 37°C for 30 days, avoiding waste and enabling delivery to the most remote areas without requiring a stringent cold chain. Other OCVs are available (VaxChora, PaxVax, United States; Dukoral, Valneva, Sweden) but at this time are not considered practical for major public health use in resource-poor settings.

Finally, a series of studies with OCVs in Haiti have demonstrated the efficacy of the Shanchol vaccine in both urban and rural settings, the feasibility of achieving high coverage rates, and the low cost of delivering this vaccine to the population. In one of the poorest urban slums of Haiti, not a single case of culture-confirmed cholera occurred between September 2013 and August 2016 in persons who had received a combined intervention ensuring household chlorination and cholera vaccination.2-4 This research complements other recent OCV studies from Guinea and South Sudan.

This information fundamentally changes the way health authorities should now consider the use of OCV in controlling cholera. Mass vaccination in Haiti would save lives, and modeling suggests that such an intervention, coupled with targeted, effective water, sanitation, and hygiene interventions, could substantially control, if not eliminate, the disease within a few years of the program’s introduction, at an affordable cost. This medium-term plan will have to be undertaken in concert with a long-term effort to realize the human right of access to clean water, a goal that will require a substantial budget and years, if not decades, to accomplish.

Control of cholera was a problem in Haiti for the 6 years before Hurricane Matthew — not only because there were insufficient resources, but also owing to the enormity of the challenge of redressing the population’s severely constrained access to clean water and sanitation.
One million doses of OCV were requested by the Haitian Ministry of Public Health and Population and authorized as part of the emergency response to Hurricane Matthew.5 Two shipments of 500,000 doses arrived in Haiti on October 24 and 25, 2016, and the vaccines have been deployed by the Ministry of Health and its partners for urgent use. We of the Special Consulting Group to the Minister of Health and Population of Haiti commend the mass-vaccination approach in the hurricane-affected areas of the south of Haiti as one part of a comprehensive emergency response. In light of recent data on vaccine efficacy, the feasibility of vaccinating in outbreak settings, and the increased availability of safe, effective, and low-cost vaccines, we urge, in addition to an emergency response to cholera in the hurricane-affected communities, that intense and reinvigorated support be provided to the government’s National Plan for the Elimination of Cholera in Haiti, including a nationwide two-dose oral cholera vaccination campaign.

Over the past six decades, several public health programs in Haiti (e.g., those focused on HIV care and treatment and control of neglected tropical diseases) have provided models for the world. The increased availability of OCVs and their rollout in a national program could provide an opportunity for the government of Haiti and the international community to demonstrate another successful strategy: comprehensive national OCV coverage combined with targeted water, sanitation, and hygiene interventions could eliminate the transmission of cholera in Haiti over the next 3 to 5 years at an affordable cost (some estimates suggest approximately $66 million). This goal is surely one to aspire to, given the human cost of maintaining the status quo.

Eliminating cholera transmission in Haiti with a combined, integrated approach at the population level would be a major achievement for the government and people of Haiti. It would also have broad implications for the control of cholera in other affected populations around the world. The time for ambitious action on cholera control and elimination in Haiti is now.

PLOS Currents: Disasters

PLOS Currents: Disasters
http://currents.plos.org/disasters/
[Accessed 14 January 2017]

Discussion
The Politics of Global Public Health in Fragile States and Ungoverned Territories
January 9, 2017 ·
The reasons for global health crises and how the world responds to them have dramatically changed over the last half century. Increasingly, natural disasters result in failure of public health and security systems leading to preventable conflict, unconventional war and unprecedented population migration. While scientific expertise exists to mitigate these failures in fragile states and ungoverned territories, inactions are mired by the lack of political will, international legal mandates, and capacity to strategically monitor multidisciplinary public health indicator failures.

PLoS Currents: Outbreaks

PLoS Currents: Outbreaks
http://currents.plos.org/outbreaks/
[Accessed 14 January 2017]

Research Article
Strategic Interactions in Antiviral Drug Use During an Influenza Pandemic
January 12, 2017
Background: The evolution of antiviral drug resistance during influenza pandemics has created widespread concern. Use of antiviral drugs is a main contributor to the evolution of drug-resistant strains. Moreover, there are recent examples of influenza viruses acquiring drug resistance seemingly without incurring a fitness penalty that reduces their transmission rate. This creates the possibility of strategic (game theoretical) interaction between jurisdictions making decisions about use of antiviral drug stockpiles.
Methods: We developed and analyzed a 2-player 2-strategy game theoretical model. Each ‘player’ (an authority in a health jurisdiction) can choose to treat with antiviral drugs at a low rate or a high rate. High treatment rates are more likely to cause emergence of a drug-resistant strain, and once a drug-resistant strain has evolved, it can spread between the two jurisdictions. We determine the Nash equilibria of the game.
Results: We show that there is a coordination game between the jurisdictions, where both players choosing a low treatment rate, or both choosing a high treatment rate, are the only stable outcomes. The socially optimal outcome occurs if both players cooperate by choosing a low treatment rate, thereby avoiding generating drug-resistant mutants. However, such cooperation may fail to materialize if the jurisdictions are closely connected through travel; if the drug-resistant mutant is tolerated (not seen as undesirable); or if the antiviral drug has partial efficacy against transmission of the drug-resistant strain.
Conclusions: Inter-jurisdictional cooperation could be essential during a severe influenza pandemic, but we know little about how jurisdictions will interact in a scenario where highly pathogenic, drug-resistant mutant strains are able to transmit as effectively as non-resistant strains. Therefore, strategic multi-population interactions during influenza pandemics should be further studied.

PLoS Neglected Tropical Diseases

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 14 January 2017)

Research Article
Forecasting Zika Incidence in the 2016 Latin America Outbreak Combining Traditional Disease Surveillance with Search, Social Media, and News Report Data
Sarah F. McGough, John S. Brownstein, Jared B. Hawkins, Mauricio Santillana
| published 13 Jan 2017 PLOS Neglected Tropical Diseases
http://dx.doi.org/10.1371/journal.pntd.0005295

PLoS One

PLoS One
http://www.plosone.org/
[Accessed 14 January 2017]

Research Article
Decreasing Seroprevalence of Measles Antibodies after Vaccination – Possible Gap in Measles Protection in Adults in the Czech Republic
Jan Smetana, Roman Chlibek, Irena Hanovcova, Renata Sosovickova, Libuse Smetanova, Peter Gal, Petr Dite
Research Article | published 13 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0170257

Research Article
Racial and Ethnic Disparities in Influenza Vaccination among Adults with Chronic Medical Conditions Vary by Age in the United States
Degan Lu, Yanru Qiao, Natalie E. Brown, Junling Wang
Research Article | published 12 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0169679

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
Recently Published Articles –
http://www.paho.org/journal/index.php?option=com_content&view=featured&Itemid=101

Special Issue on HIV/AIDS in the Americas
Editorial | Published 13 January
What will it take to end AIDS in the Americas?
[¿Qué se necesita para terminar con el sida en la Región de las Américas?]
Carissa F. Etienne

Overview Published 13 January |
HIV/AIDS prevention, care and treatment in the Region of the Americas:
achievements, challenges and perspectives
[Prevención, atención y tratamiento de la infección por el VIH/sida en la Región de
las Américas: logros, retos y perspectivas]
Freddy Pérez, Giovanni Ravasi, J.Peter Figueroa, Beatriz Grinsztejn, Mary Kamb, Omar Sued, and Massimo Ghidinelli

Vaccine – Volume 35, Issue 2, Pages 201-410 (5 January 2017)

Vaccine
Volume 35, Issue 2, Pages 201-410 (5 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/2

Original Research Article

Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand
Original Research Article
Pages 299-304
Tawee Chotpitayasunondh, Pornpimol Pruekprasert, Thanyawee Puthanakit, Chitsanu Pancharoen, Auchara Tangsathapornpong, Peninnah Oberdorfer, Pope Kosalaraksa, Olarn Prommalikit, Suwimon Tangkittithaworn, Phirangkul Kerdpanich, Chonnamet Techasaensiri, Joanna Korejwo, Sunate Chuenkitmongkol, Guy Houillon
Abstract
Background
Japanese encephalitis is a mosquito-borne viral disease endemic in most countries in Asia. A recombinant live, attenuated Japanese encephalitis virus vaccine, JE-CV, is licensed in 14 countries, including Thailand, for the prevention of Japanese encephalitis in adults and children.
Methods
This was a prospective, phase IV, open-label, multicentre, safety study of JE-CV conducted from November 2013 to April 2015, to evaluate rare serious adverse events (AEs). JE-CV was administered to 10,000 healthy children aged 9 months to Results
The median age of participants was 1.1 years in Group 1 and 3.8 years in Group 2. SAEs were reported in 204 (3.0%) participants in Group 1 and 59 (1.9%) participants in Group 2. Among a total of 294 SAEs in 263 participants, only three events occurring in two participants were considered related to vaccination. All three cases were moderate urticaria, none of which met the definition of AEs of special interest for hypersensitivity. AEs of special interest were reported in 28 (0.4%) participants in Group 1 and 4 (0.1%) participants in Group 2; none were considered related to vaccination. Febrile convulsion was the most frequently reported AE of special interest: 25 (0.4%) participants in Group 1; and 2 (<0.1%) in Group 2. There were no cases of Japanese encephalitis reported. No Grade 3 immediate systemic AEs were reported after any JE-CV vaccination.
Conclusions
Our study did not identify any new safety concerns with JE-CV and confirms its good safety profile.
This study was registered on http://www.clinicaltrials.gov (NCT01981967; Universal Trial Number: U1111-1127-7052)

Vaccine – Volume 35, Issue 2, Pages 201-410 (5 January 2017)

Vaccine
Volume 35, Issue 2, Pages 201-410 (5 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/2

Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country
Original Research Article
Pages 321-328
Marjahan Akhtar, Firdausi Qadri, Taufiqur R. Bhuiyan, Sarmin Akter, Tanzeem A. Rafique, Arifuzzaman Khan, Laila N. Islam, Amit Saha, Ann-Mari Svennerholm, Anna Lundgren
Abstract
Immune responses to oral enteric vaccines in children and infants may be influenced by factors such as age, previous priming with related microorganisms and breast feeding. In this study, we aimed to determine optimal time points to assess immune responses to oral enteric vaccines in different clinical specimens. This was done by investigating antibody secreting cell (ASC) and fecal antibody responses on different days after vaccination using the licensed oral cholera vaccine Dukoral, containing cholera toxin B-subunit (rCTB) and inactivated Vibrio cholerae bacteria, as a model vaccine.
Two vaccine doses were given 2 weeks apart to infants (6–11 months), young children (12–18 months), toddlers (19 months–5 years) and adults in a cholera endemic country (Bangladesh). IgA ASC responses, as determined by the antibodies in lymphocyte supernatant (ALS) assay, plasma IgA and IgG responses and secretory IgA (SIgA) responses in extracts of fecal samples were evaluated 4/5 and 7 days after each vaccination.
After the first vaccine dose, anti-CTB ALS IgA responses in adults and toddlers were high and comparable on day 5 and 7, while responses were low and infrequent in young children. After the second dose, highest ALS responses were detected on day 5 among the time points studied in all age groups and the responses declined until day 7. In contrast, plasma IgA and IgG anti-CTB responses were high both on day 5 and 7 after the second dose. Fecal SIgA responses in young children and infants were highest on day 7 after the second dose.
Our results suggest that ASC/ALS responses to two doses of the oral cholera vaccine Dukoral and related oral vaccines should be analyzed earlier than previously recommended (day 7) at all ages. Fecal antibody responses should preferably be analyzed later than ASC/ALS responses to detect the highest antibody responses.

Vaccine – Volume 35, Issue 2, Pages 201-410 (5 January 2017)

Vaccine
Volume 35, Issue 2, Pages 201-410 (5 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/2

Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia
Original Research Article
Pages 345-352
J.F. Reyes, J.G. Wood, P. Beutels, K. Macartney, P. McIntyre, R. Menzies, N. Mealing, A.T. Newall
Abstract
Background
Universal vaccination against rotavirus was included in the funded Australian National Immunisation Program in July 2007. Predictive cost-effectiveness models assessed the program before introduction.
Methods
We conducted a retrospective economic evaluation of the Australian rotavirus program using national level post-implementation data on vaccine uptake, before-after measures of program impact and published estimates of excess intussusception cases. These data were used as inputs into a multi-cohort compartmental model which assigned cost and quality of life estimates to relevant health states, adopting a healthcare payer perspective. The primary outcome was discounted cost per quality adjusted life year gained, including or excluding unspecified acute gastroenteritis (AGE) hospitalisations.
Results
Relative to the baseline period (1997–2006), over the 6 years (2007–2012) after implementation of the rotavirus program, we estimated that ∼77,000 hospitalisations (17,000 coded rotavirus and 60,000 unspecified AGE) and ∼3 deaths were prevented, compared with an estimated excess of 78 cases of intussusception. Approximately 90% of hospitalisations prevented were in children Conclusion
The inclusion of herd impact and declines in unspecified AGE hospitalisations resulted in the value for money achieved by the Australian rotavirus immunisation program being substantially greater than predicted by pre-implementation models, despite the potential increased cases of intussusception. This Australian experience is likely to be relevant to high-income countries yet to implement rotavirus vaccination programs.

* * * *

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Papillomavirus Research
In Press, Accepted ManuscriptNote to users
Available online 6 January 2017
Human papillomavirus (HPV) in young woman in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types
C Tanton, D Mesher, S Beddows, K Soldan, S Clifton… – Papillomavirus Research, 2017
Abstract
Background
In 2008, the UK introduced an HPV immunisation programme in girls. Population-based prevalence estimates of bivalent (HPV-16/18), quadrivalent (HPV-6/11/16/18) and 9-valent (HPV-6/11/16/18/31/33/45/52/58) vaccine types, and comparison over time, are needed to monitor impact, evaluate effectiveness and guide decision-making on vaccination strategies.
Methods
The third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) in 2010-12, tested urine for HPV from 2,569 sexually-experienced women aged 16–44. We report type-specific HPV prevalence and compare results with 1,798 women in Natsal-2 (1999–2001) using age-adjusted prevalence ratios (APR).
Findings
In Natsal-3, 4.2% of women aged 16-44y were positive for HPV-16/18 and 2.9% for HPV-6/11. In 16–20 year olds, 4.5%, 10.8% and 20.7% had at least one bivalent, quadrivalent or 9-valent vaccine type, respectively. Three-dose vaccine coverage was 52.0% in women aged 18-20y. In this age group, HPV-16/18 prevalence was lower in Natsal-3 than Natsal-2 (5.8% vs 11.2%; APR=0.48[95%CI: 0.24–0.93]), however, prevalences of HPV-6/11, HPV-31/33/45 and HPV-52/58 were unchanged. HPV-16/18 prevalence was also unchanged in women aged 21-44y (APR=0.85[0.61–1.19).
Interpretation
These probability surveys provide evidence of the impact of the bivalent immunisation programme. Reductions were specific to HPV-16/18 and to the age group eligible for vaccination. However, substantial vaccine-preventable HPV remains.

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Journal of the American Pharmacists Association
Article in Press
Interventions to improve dissemination and implementation of Hepatitis B vaccination in patients with diabetes
Thomas Matta, Katherine O’Neal, Jeremy Johnson, Sandra Carter, Michelle Lamb, Lourdes Planas
DOI: http://dx.doi.org/10.1016/j.japh.2016.11.004
Abstract
Objective
The purpose of this study was to assess provider awareness of routine vaccinations recommended for patients with diabetes and to determine whether pharmacist-led interventions are associated with increased provider implementation of recommendations for hepatitis B vaccination.
Methods
This study was conducted in 3 phases at 2 outpatient clinics affiliated with an academic institution. In phase 1, adults with diabetes who visited the clinics between January and November 2012 and who were eligible for the hepatitis B vaccine were identified. In phase 2, medical residents were surveyed twice for vaccine recommendations and reasons for (not) recommending the hepatitis B vaccine, specifically. Residents were then provided a pharmacist-led in-service about hepatitis B vaccine recommendations. The third phase was initiated in April 2013, following postintervention observation from December 2012 through March 2013.
Results
Forty-eight of 100 (48%) medical residents attended the in-service and completed both surveys, with 77% indicating they did not recommend the hepatitis B vaccine. During phase 1, 1441 patients were identified, 0.6% (n = 8) of whom had received at least the first dose of the series. In phase 3, 946 patients were identified with 1.7% (n = 16) having received at least the first dose (P = 0.007).
Conclusion
An attempt to disseminate updated recommendations to providers via educational in-service was successful in increasing the percentage of eligible patients vaccinated with the hepatitis B vaccine.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

Forbes
http://www.forbes.com/
Accessed 14 January 2017
AMA And Family Doctors Rip Trump Vaccine Commission
Jan 10, 2017
Bruce Japsen, Contributor
The American Medical Association and the American Academy of Family Physicians Tuesday night blasted the Trump administration idea that a new commission on vaccine safety was needed.

Foreign Policy

Home


Accessed 14 January 2017
Donald Trump and the Anti-Vaxxer Conspiracy Theorists
The president-elect’s dangerous views on the safety of vaccines threaten the lives of millions of Americans.
11 January 2017
By Laurie Garrett
Things are getting down and dirty now. And millions of lives are at stake. I cannot possibly state strongly enough how dangerous it is that President-elect Donald Trump has embraced the notion that vaccination is the cause of autism.
Robert F. Kennedy Jr., a celebrated vaccine skeptic, met with Trump on Jan. 10. Speaking to reporters outside Trump Tower in Manhattan after the meeting, Kennedy said he will chair a commission “on vaccine safety and scientific integrity” at Trump’s request, because, “we ought to be debating the science.”…

The Guardian
http://www.guardiannews.com/
Accessed 14 January 2017
Opinion
Trump’s vaccine conspiracy theories are a threat to your children
Vaccines have been shown safe and effective. When he hints otherwise, the president-elect is gambling with young lives
13 January 2017
Celine Gounder
Whether Trump is creating a commission on vaccine safety or autism, the message is clear. Trump is offering prominent support to the conspiracy theory that vaccines cause autism. The science on vaccines is very clear: they are safe and effective.

New Yorker
http://www.newyorker.com/
Accessed 14 January 2017
Trump’s Dangerous Support for Conspiracies About Autism and Vaccines
By Michael Specter
January 11, 2017

New York Times

Accessed 14 January 2017
Anti-Vaccine Activist Says Trump Wants Him to Lead Panel on Immunization Safety
10 January 2017

Washington Post
http://www.washingtonpost.com/
The United States already has a vaccine safety commission. And it works really well, experts say.
The federal panel was established more than 50 years ago and consists of medical and scientific experts as well as a consumer representative.
Lena H. Sun | National/health-science | Jan 13, 2017

The race to develop a vaccine: Scientists inch closer to preventing Zika
12 January 2017
Several companies and U.S. government institutions are racing to develop a vaccine to prevent infection from the Zika virus. The vaccine candidates to date, which use a variety of approaches, are in different stages of development…

The Post’s View: If Trump keeps stoking vaccine fears, he will endanger children’s lives
The president-elect’s meeting with a leading vaccine skeptic sent a troubling signal about a critical children’s health issues.
Editorial Board | Editorial-Opinion | Jan 12, 2017
PRESIDENT-ELECT Donald Trump’s transition team tried to tamp down the report from leading vaccine skeptic Robert F. Kennedy Jr. that Mr. Trump had asked him to lead a new panel on the safety of childhood inoculations. The president-elect, we were told, is only exploring the possibility of forming a government commission on autism. But by even entertaining the idea, Mr. Trump — who has his own troubling history when it comes to vaccine safety — gives new life to debunked conspiracy theories tying autism to vaccines. That in turn endangers children’s lives.
Mr. Trump met Tuesday with Mr. Kennedy, a longtime opponent of mandatory vaccination laws who once characterized the shots children receive to guard against illness as a holocaust. The meeting at Trump Tower, which Mr. Kennedy told reporters was requested by Mr. Trump, caused immediate and understandable concern in the medical community.
“It gives it a quasi-legitimacy that I frankly find frightening,” William Schaffner, a professor of preventive medicine and infectious diseases at Vanderbilt University, told the New York Times. Theories about a link between vaccines and conditions such as autism have been thoroughly discredited in numerous scientific studies that have established — without any question — the safety of vaccines.
Yet Mr. Trump, 10 days away from taking the oath of office for president, thought it important enough to meet with a leading proponent of conspiracy theories about vaccines, someone who, by the way, holds a law — not a medical — degree. Mr. Trump’s past comments about vaccines — “massive combined inoculations to small children is the cause for big increase in autism,” he tweeted in 2012 — betray an ignorant distrust of vaccines.
If Mr. Trump wants to make attacking autism a priority, he should be applauded. But he needs to go about it responsibly. Experts will tell him that the diagnosis of autism is more prevalent than in the past not because there is an “epidemic,” as he once claimed, but because the definition of autism spectrum disorder has grown more inclusive. And they will assure him there is no connection to vaccines. He will endanger the health of millions of children if he fans doubts about vaccine safety.

Vaccines and Global Health: The Week in Review 14 January 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: vaccines-and-global-health_the-week-in-review_14-january-2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Vaccines and Global Health: The Week in Review – 7 January 2017

Vaccines and Global Health: The Week in Review
7 January 2017
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is also posted in pdf form and as a set of blog posts at https://centerforvaccineethicsandpolicy.wordpress.com/. This blog allows full-text searching of over 8,000 entries.
Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request an email version: Vaccines and Global Health: The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EST/U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Editor’s Note:
Vaccines and Global Health: The Week in Review resume publication with this 7 January 2017 edition following the end-of-year holiday period.

Milestones :: Perspectives

Milestones :: Perspectives

EBOLA/EVD [to 7 January 2017]
http://www.who.int/ebola/en/
“Threat to international peace and security” (UN Security Council)

Editor’s Note:
A special edition of Vaccines and Global Health: The Week in Review was published on 23 December, providing a summary of major announcements and analysis on Ebola vaccine development and trial results as published in The Lancet – Online First on 22 December 2016, with a 23 December 2016 news release by WHO. The full text of this edition is available here: https://centerforvaccineethicsandpolicy.net/2017/01/02/vaccines-and-global-health-the-week-in-review-ebola-vaccines-update/

:::::::

Emergencies

Emergencies

WHO Grade 3 Emergencies [to 7 January 2017]
Iraq
:: WHO’s response to trauma cases saves hundreds of lives in Iraq
5 January 2016 – Since 17 October 2016, WHO has supported the Government of Iraq and the Kurdish Regional Government with emergency lifesaving health services, including emergency medicines and other medical supplies like trauma and surgery kits. These supplies are meant to support the increasing number of trauma cases received at trauma stabilization points and en route to the final points of performing surgery.

The Syrian Arab Republic –
:: Aid workers share experiences of evacuations from eastern Aleppo, Syria
3 January 2017 – Intensified fighting in eastern Aleppo starting in July 2016 resulted in thousands of people injured and killed, and has deprived the civilian population of essential services, including health care. On 13 December, a plan to evacuate civilians was announced by WHO and partners. The first evacuations from besieged neighbourhoods in eastern Aleppo took place 15 December 2016.
:: Regional Situation Reports
December highlights
…WHO Syria: Provided over 346,000 treatments across conflict lines to Aleppo and Homs governorates. This represents 45% of 780,000 treatments delivered this month.
…WHO Iraq: Concluded the second round of the national oral cholera vaccination campaign between 07 and 09 December in the Kurdistan Region.
…WHO Jordan: Assisted in establishing a polio control room under the leadership of the Ministry of Health, which includes WHO, UNICEF, nongovernmental organizations and Royal Medical Services.
…WHO Turkey: Completed a polio campaign in Kobani area in northern Syria covering more than 17 000 children under 5 years of age. Kobane is accessed for the first time since December 2014 due to security tensions and subsequent border blockade.

South Sudan –
:: Read the latest cholera situation report pdf, 1.08Mb 29 December 2016
[Excerpt]
ORAL Cholera Vaccination (OCV)
To increase immunity, there is a need for two rounds of oral cholera vaccination. The population of Bentiu PoC when the last two rounds were conducted in June 2015 was about 70,000. The current population has increased to 120,000. OCV coverage survey conducted by WHO/IOM in December 2016 showed that the OCV coverage stands at 40%. This is therefore not adequate to prevent transmission…

Nigeria – No new announcements identified.
Yemen – No new announcements identified.

WHO Grade 2 Emergencies [to 7 January 2017]
Cameroon – No new announcements identified.
Central African Republic – No new announcements identified.
Democratic Republic of the Congo – No new announcements identified.
Ethiopia – No new announcements identified.
Libya – No new announcements identified.
Myanmar – No new announcements identified.
Niger – No new announcements identified.
Ukraine – No new announcements identified.

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises.
Iraq
:: Iraq: Mosul Humanitarian Response Situation Report #14 (26 December 2016-1 January 2017)

Syria
:: UNHRD Operations Overview: Support to Current Humanitarian Crises (as of 04 January 2017) 5 Jan 2017
:: Syrian Arab Republic: Aleppo Situation Report No. 12 (04 January 2017) [EN/AR]
:: Statement on Syria UN Humanitarian Chief 31 Dec 2016

Yemen – No new announcements identified.

Corporate Emergencies
Haiti
Haiti: Hurricane Matthew – Situation Report No. 30 (26 December 2016)
…62,000 Children received routine vaccinations Source: UNICEF

::::::

UNICEF [to 7 January 2017]

UNICEF [to 7 January 2017]

http://www.unicef.org/media/media_89711.html
PORT-AU-PRINCE, 4 January 2017
Three months after Matthew, UNICEF and its partners continue to bring assistance to affected population
[Text bolding by Editor]
Almost three months after hurricane Matthew, UNICEF and its partners continue to deliver humanitarian aid to those most affected by the category 4 storm.

Over 2 million people including 900,000 children were affected by the hurricane, of which 1.4 million require humanitarian assistance including 600,000 children.  In addition to the personal losses of homes and crops, over 716 schools, and many health facilities and the existing sanitation infrastructure all suffered damage.

Together with the government of Haiti, UNICEF and its partners have been able to ensure safe water is available daily to over 281,000 individuals, including over 118,000 children.  UNICEF contributed to the cholera vaccination campaign, in November that reached 807,395 people, ensuring the delivery also of information regarding the prevention of cholera. Over 309,213 children between the ages of 1-14 years are included in this figure. In the health sector, UNICEF has restored the cold-chain systems of 37 facilities, has equipped 35 malnutrition outpatient treatment centers in Grand’Anse and South and two inpatient facilities in each of these departments. In education, UNICEF has completed the restoration of 14 schools, with another 107 in various stages of progress.  These restored schools have made it possible for 4,200 students to return to class.  In total, it’s expected that over 36,000 students will return to the schools rehabilitated by UNICEF.

UNICEF works closely with communities on malnutrition that continues to affect children and adults as they struggle to recover from the extended drought and the subsequent effects of hurricane Matthew including persistent risk of disease and loss of livelihood.  UNICEF protection interventions are supporting families that have lost their livelihoods, aimed at preventing child separation; it is common for parents to place their children in residential care facilities in the often-false expectation that they will receive access to education that parents can no longer afford.  Economic stress is also known to lead to violence, and increased social tension which combine to increase the potential for child abuse and neglect…

“Three months after Matthew, we can already see improvements: safe water is increasingly available, the vast majority of schools have reopened as have a number of health facilities; and areas that are the most difficult to access are receiving assistance. UNICEF is continuing to fulfil its mandate and obligations to emergency and development efforts, “said Marc Vincent, UNICEF Representative in Haiti…

::::::

Zika virus [to 7 January 2017]

Zika virus [to 7 January 2017]
http://www.who.int/emergencies/zika-virus/en/

Zika situation report – 05 January 2017
Full report: http://apps.who.int/iris/bitstream/10665/252762/1/zikasitrep5Jan17-eng.pdf?ua=1
Key Updates
:: Countries and territories reporting mosquito-borne Zika virus infections for the first time in the past week:
… None
:: Countries and territories reporting microcephaly and other central nervous system (CNS) malformations potentially associated with Zika virus infection for the first time in the past week:
… None
:: Countries and territories reporting Guillain-Barré syndrome (GBS) cases associated with Zika virus infection for the first time in the past week:
… None
:: This is the last weekly situation report. Going forward, the reports will be published every two weeks. The next report will be issued on 19 January.
Analysis
:: Overall, the global risk assessment has not changed. Zika virus continues to spread geographically to areas where competent vectors are present. Although a decline in cases of Zika infection has been reported in some countries, or in some parts of countries, vigilance needs to remain high.

Zika Open [to 7 January 2017]
[Bulletin of the World Health Organization]
:: All papers available here
No new papers identified.

CDC Highlights Significant Contributions in the Fight against Zika in 2016
FRIDAY, DECEMBER 30, 2016
Seventy years after CDC was founded to fight mosquitoes that carried malaria, CDC found itself entrenched in combat with another mosquito-borne illness, Zika virus.

::::::

POLIO [to 7 January 2017]

POLIO [to 7 January 2017]
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 4 January 2017
:: Summary of newly-reported viruses this week (see country-specific sections below for further details): Pakistan:  three positive environmental samples (wild poliovirus type 1 – WPV1)

:: New this week: new webinars on outbreak response – check the last item in Resources for Polio Eradicators to learn about outbreak response protocols, cold chain logistics, and evaluating communications in outbreaks, among others. These webinars complement the guidelines and protocols developed by GPEI partners.

Country Updates [Selected Excerpts]
Pakistan
:: Three WPV1-positive environmental samples were reported in the past week from Quetta, Balochistan, collected on 12 December; Rawalpindi, Punjab, collected on 10 December; and Peshawar, Khyber Pakhtunkhwa (KP), collected on 10 December.
:: An outbreak response activity using monovalent oral polio vaccine type 2 (mOPV2) is being implemented this week in Quetta, in response to a confirmed circulating vaccine-derived poliovirus type 2 (cVDPV2) in the area, in line with internationally-agreed outbreak response protocols.  The Ministry of Health, supported by the World Health Organization (WHO) and partners, is further strengthening active search for cases of acute flaccid paralysis (AFP), and conducting an in-depth field investigation to more clearly ascertain the extent of circulation of the cVDPV2.

Pakistani city launches new polio campaign after rare strain found
Reuters By Gul Yousafzai |
2 January 2017 QUETTA, Pakistan
Pakistan began a special five-day polio immunisation campaign in the southwestern city of Quetta on Monday for children under five after a rare strain of the virus was found in sewage samples, officials said.
Local officials said they had recruited Muslim clerics to promote the immunisations for 400,000 children after past programmes were met with resistance and even violence by extremists.
“The religious leaders were … asking the people to give their children anti-polio drops in their sermons in the mosques in rural areas of Baluchistan,” said Syed Faisal Ahmed, coordinator of the local Emergency Operation Centre.
Pakistan is one of just three countries in the world, along with Afghanistan and Nigeria, that have endemic polio, a once-common childhood virus that can cause paralysis or death.
Last year, Pakistan reported a record low of 19 cases, Ahmed said, with only one of them in Baluchistan province, of which Quetta is the capital.
The new campaign follows the detection of the rare Type 2 strain of polio in sewage samples taken by the World Health Organization in November, Ahmed said. The WHO reported the findings last week.
No cases of the Type 2 strain have been reported in humans in Quetta but it has been added to the vaccine as a precaution. The more common type of polio is Type 1, with no human cases of Type 2 reported for more than a decade.
“We have achieved major goals in combating polio disease, but still we have to strive more to declare Pakistan a polio-free country,” Ahmed said…

::::::
::::::

WHO & Regional Offices [to 7 January 2017]

WHO & Regional Offices [to 7 January 2017]

140th session of the Executive Board
23 January–1 February 2017, Geneva

Working as one UN for environmental health
3 January 2017 – There are many compelling reasons to clean up the global environment. One of the most pressing is that a polluted environment is deadly: every year, 1 in 4 people die from diseases associated with air, water or soil pollution. The United Nations Environment Programme (UNEP), the World Meteorological Organization (WMO) and WHO are creating a global mechanism to bring together the environment and health sectors.
Commentary

Highlights
Response to trauma cases saves hundreds of lives in Iraq
January 2017 – Since 17 October 2016, WHO has supported the Government of Iraq and the Kurdish Regional Government with emergency lifesaving health services, including emergency medicines and other medical supplies like trauma and surgery kits.

Aid workers share experiences of evacuations from eastern Aleppo, Syria
January 2017 – Intensified fighting in eastern Aleppo starting in July 2016 resulted in thousands of people injured and killed, and has deprived the civilian population of essential services, including health care. The first evacuations from besieged neighbourhoods in eastern Aleppo took place 15 December 2016.

Weekly Epidemiological Record, 6 January 2017, vol. 92, 1 (pp. 1–12)
:: Status of new vaccine introduction – worldwide, September 2016
:: Detection of Sabin-like type 2 poliovirus after global cessation of trivalent oral poliovirus vaccine in Hyderabad and Ahmedabad, India, August–September 2016

:: WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
No new announcements identified.

WHO Region of the Americas PAHO
:: Toward the end of polio: The vaccine ‘switch’ in the Americas (12/29/2016)
:: 2016: the year Zika evolved from an emergency into a long-term public health challenge (12/29/2016)

WHO South-East Asia Region SEARO
No new announcements identified.

WHO European Region EURO
:: Experiences of evacuations from eastern Aleppo, Syria 06-01-2017

WHO Eastern Mediterranean Region EMRO
:: WHO’s response to trauma cases saves hundreds of lives in Iraq
5 January 2017 – Since 17 October 2016, WHO has supported the Government of Iraq and the Kurdish Regional Government with emergency lifesaving health services, including emergency medicines and other medical supplies like trauma and surgery kits. These supplies are meant to support the increasing number of trauma cases received at trauma stabilization points and en route to the final points of performing surgery.
:: WHO welcomes continued support from the Government of France and European Union Member States 6 January 2017
:: WHO provides lifesaving HIV medicines in Benghazi, Libya 3 January 2017

WHO Western Pacific Region
No new announcements identified.

::::::
::::::

CDC/ACIP [to 7 January 2017]

CDC/ACIP [to 7 January 2017]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/
Press Release
FRIDAY, DECEMBER 30, 2016
CDC Highlights Significant Contributions in the Fight against Zika in 2016
Seventy years after CDC was founded to fight mosquitoes that carried malaria, CDC found itself entrenched in combat with another mosquito-borne illness, Zika virus.

MMWR Weekly January 6, 2017/No. 52
[Excerpts]
:: Human Rabies — Puerto Rico, 2015
:: Zika Virus —10 Public Health Achievements in 2016 and Future Priorities
:: Notes from the Field: Compliance with Postexposure Prophylaxis for Exposure to Bacillus anthracis Among U.S. Military Personnel — South Korea, May 2015
:: Notes from the Field: Detection of Sabin-Like Type 2 Poliovirus from Sewage After Global Cessation of Trivalent Oral Poliovirus Vaccine — Hyderabad and Ahmedabad, India, August–September 2016

::::::
::::::

Announcements [to 7 January 2017]

Announcements

Human Vaccines Project [to 7 January 2017]
http://www.humanvaccinesproject.org/media/press-releases/
January 4, 2017
Moderna Joins the Human Vaccines Project to Help Advance Fundamental Understanding of the Immune System
Public-Private Consortium Collaborating to Generate New Immunological Insights, Accelerate Development of Vaccines and Immunotherapies
CAMBRIDGE, Mass. — Moderna Therapeutics, a clinical stage biotechnology company pioneering messenger RNA (mRNA) Therapeutics to create a new generation of transformative medicines for patients, announced today that it will join the Human Vaccines Project, a non-profit public-private partnership focused on decoding the human immune system to accelerate the development of vaccines and immunotherapies against major infectious diseases and cancer. Moderna will join the global, cross-sector consortium of academic research centers, biopharmaceutical companies, governments and non-profit organizations in sharing knowledge and resources to generate key insights about immunological protection, and address primary scientific hurdles to developing new vaccines and immunotherapies.

“We are proud to support the important efforts of the Human Vaccines Project to unlock basic understanding of the immune system and translate this knowledge to accelerate infectious disease vaccines and cancer immunotherapies,” said Michael Watson, President of Valera, Moderna’s infectious disease-focused venture. “Collaborating with biopharma, academic, non-profit and government organizations has been a key focus of Moderna’s strategy to advance the promise of mRNA science for patients. We look forward to contributing to this consortium in kind, helping advance knowledge about human immunity that, ultimately, could help people around the world.”

Moderna currently has four mRNA-based infectious disease vaccines in clinical study and another four infectious disease vaccines advancing toward the clinic. The company is also developing an mRNA-based personalized cancer vaccine…

“We are honored to have Moderna join the Human Vaccines Project’s efforts to address the immunologic challenges impeding development of new and improved vaccines and immunotherapies for major infectious diseases and cancers,” said Wayne C. Koff, President and CEO, Human Vaccines Project. By harnessing recent technological advances from biomedical, computational, and engineering sciences, including Moderna’s transformative mRNA platform, the Project offers the potential to decode the human immune system, accelerate product development, and usher in a new era of global disease prevention.”

::::::

Coalition for Epidemic Preparedness Innovations (CEPI) [to 7 January 2017]
http://cepi.net/
CEPI Newsletter 6 January 2017
[Excerpts]
Message from the Interim CEPI CEO
“We have a new year ahead of us. The end of last year provided a gift for all of us – the
Ebola vaccine that has been tried out in Guinea during the outbreak in 2015 has proven to
be highly protective against Ebola virus disease. CEPI grew out of both the good and bad
experiences from the Ebola outbreak; the global mechanisms did not work as intended,
but a tremendous collaborative effort made them work. The confirmation of the
protectiveness of the vaccine, as documented in the Lancet, demonstrates that we are
able to achieve great things when we work together across borders. Let us all celebrate
this is as an inspiration for our future work through CEPI.
A new year is ahead of us, and important milestones are right around the corner. Already
on 19 January CEPI will launch officially at the World Economic Forum’s annual meeting
in Davos…
John-Arne Røttingen, Interim CEPI CEO

Partners Forum
In an earlier newsletter, news about the establishment of a CEPI Partners Forum was
shared. We are now pleased to announce that the Partners Forum is officially open for
sign-on. To become a member of the Partners Forum, kindly follow this link and sign on to
the online “Partners Statement”. Here you will also find more information about the forum
and its envisioned functions.

::::::

PATH [to 7 January 2017]
http://www.path.org/news/index.php
Announcement | December 27, 2016
PATH welcomes Peggy Johnson and Deanna Oppenheimer to its board of directors
PATH’s board of directors has voted to appoint Peggy Johnson and Deanna Oppenheimer to the board. Ms. Johnson brings diverse experience in business development, strategic partnerships, and investment management, while Ms. Oppenheimer enhances the board’s expertise in global finance, brand marketing, banking and communications…

::::::

The Vaccine Confidence Project [to 7 January 2017]

The Vaccine Confidence Project [to 7 January 2017]
http://www.vaccineconfidence.org/
Confidence Commentary
Message for the New Year: The answer is blowin’ in the wind
Heidi Larson | 4 Jan, 2017
[Excerpt]
…If we look around at the public health landscape at the start of 2017, there are a number of challenges ahead, not the least of which is growing anti-microbial resistance, which is becoming increasingly urgent. Another area, which is keeping a number of people awake at night and which I would consider the number one concern of the Vaccine Confidence Project, is the threat of a highly fatal flu pandemic.

In a 2016 year-end interview on BBC Radio with the UK’s Chief Medical Officer Sally Davies, Bill Gates revealed his concerns about the vulnerability of the world to the next flu pandemic. In short, his assessment was that we’re not ready for the next “big one” when it comes to epidemics. “I cross my fingers that some epidemic like a flu doesn’t come along in the next 10 years,” says Mr Gates, confident that we will develop better tools and approaches over the next decade, but soberly expressing concerns that if we are faced with a quickly spreading fatal strain of the flu today, “it would be a tragedy.”  In short, we couldn’t manage it.

At the end of November, in an interview in the Wall Street Journal, the Director of the US Centers for Disease Control, Tom Frieden, shared a similar sentiment. “Frankly, pandemic influenza is what worries us most.”

According to WHO, the “normal” seasonal flu epidemics cause serious illness in three to five million people around the world and between 250,00-500,000 people die of influenza every year. And, those are not the most virulent strains.

If we reflect on the global panic around Ebola’s fatal spread, the total death toll was just over 11,000. This is not to underestimate the extensive social and economic turmoil it also caused, but just to put the flu risk in perspective. The 1918 ‘Spanish’ flu pandemic infected 500 million people across the world, spread as far as remote Pacific islands and the Arctic, and resulted in the deaths of 50 to 100 million people (three to five percent of the world’s population).

Why is there such a difference between our more complacent attitude towards influenza versus more panic-prone anxieties around Ebola? Known versus unknown. Familiar versus unfamiliar.  One of the challenges for pandemic flu preparedness  is the widespread perception that “it’s just the flu”.

If I were to choose one new year’s message, it is that we need to work harder in peaceful times to build resilience. We can start by taking flu more seriously – ourselves, our families and neighbours…

::::::

Industry Watch [to 7 January 2017]

Industry Watch [to 7 January 2017]
:: Sanofi Pasteur and MSD end joint vaccines business in Europe
Paris, France – January 2, 2017 – Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). Sanofi Pasteur and MSD will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines business into their operations. The change in operations took effect January 1, 2017.
Since its announcement in March 2016, the project has been managed in an open dialogue with the SPMSD employees, unions and relevant external stakeholders, in compliance with the applicable rules and regulations. During the transitional period following the announcement of the ending of the joint-venture, SPMSD and Sanofi and Merck, its shareholders, have been focused on a smooth and orderly transition while achieving their public healthcare goals and upholding their commitments to their employees, customers and business partners.
Each company will be able to define its own vaccines strategy to benefit public health and create value for patients, healthcare professionals, and payers. In November 2015, as part of its strategic roadmap 2020, Sanofi announced that it would reshape its portfolio, namely through sustained leadership in vaccines.

:: PaxVax Partners with National Institutes of Health and Department of Defense to Develop a New Virus-Like Particle Vaccine to Fight the Spread of Chikungunya
REDWOOD CITY, Calif., Jan. 5, 2017 /PRNewswire/ — PaxVax announced today its partnership with the National Institutes of Health (NIH) and United States Department of Defense (DoD) on its chikungunya vaccine program. According to the terms of the collaboration, PaxVax has in-licensed the NIH virus-like particle (VLP) vaccine technology for chikungunya with plans to bring the vaccine through full commercialization. NIH has already completed a phase 1 trial, and is currently assessing the vaccine in a phase 2 trial. For the past year, PaxVax has been working to develop a commercial manufacturing process and the necessary release assays. In addition to conducting its own trials, PaxVax will work with the Walter Reed Army Institute of Research (WRAIR)—a DoD biomedical research laboratory—to conduct an additional clinical trial to assess the potential advantages of an alum adjuvant in the vaccine formulation.

:: US FDA Grants Orphan Drug Designation to Yisheng Biopharma’s PIKA Rabies Vaccine
Jan 04, 2017
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead vaccine candidate, PIKA rabies vaccine, which is an innovative rabies vaccine independently developed by Yisheng Biopharma, using its proprietary toll-like receptor-3 (TLR-3) activation technology.

::::::
::::::

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders
Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

No new content identified.

* * * *

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Infection Control – January 2017 Volume 45, Issue 1, p1-104, e1-e22

American Journal of Infection Control
January 2017 Volume 45, Issue 1, p1-104, e1-e22
http://www.ajicjournal.org/current

Commentaries
Our health care workers need more than infection prevention best practice while caring for patients with novel and highly pathogenic infections
Mary-Louise McLaws
p4–5
Published online: November 14, 2016
[No abstract]

American Journal of Preventive Medicine – January 2017 Volume 52, Issue 1, p1-134, e1-e32

American Journal of Preventive Medicine
January 2017 Volume 52, Issue 1, p1-134, e1-e32
http://www.ajpmonline.org/current

Research Articles
Herpes Zoster Vaccine Coverage in Older Adults in the U.S., 2007–2013
Dongmu Zhang, Kelly Johnson, Chrisann Newransky, Camilo J. Acosta
e17–e23
Published online: October 26, 2016
Open Access
Abstract
Introduction
This study aimed to assess the coverage of herpes zoster (HZ) vaccine among a large cohort of insured individuals aged ≥50 years from 2007 to 2013, and to determine the factors associated with being vaccinated for adults aged ≥60 years.
Methods
This was a retrospective, observational study using the MarketScan® database conducted in 2015. The study population was U.S. adults aged ≥60 years during 2007−2013 and 50–59 years during 2011–2013. The claims of each eligible subject were evaluated post–index date to assess HZ vaccine uptake. Multivariate analyses were performed to understand factors associated with receiving HZ vaccine.
Results
A total of 6,746,476 adults aged ≥60 years and 6,770,294 adults aged 50–59 years were identified. By 2013, 1.7% of adults aged 50–59 years, 23.9% of adults aged 60–64 years, and 14.5% of adults aged ≥65 years received HZ vaccine. Adults aged ≥65 years were less likely to receive HZ vaccine than those aged 60–64 years (hazard ratio [HR]=0.543; 95% CI=0.539, 0.547). Adults who were female, immunocompetent, and had more outpatient hospital, doctor office, and pharmacy visits were more likely to receive HZ vaccine. Adults who received influenza vaccine were more likely to receive HZ vaccine (HR=1.841; 95% CI=1.830, 1.853).
Conclusions
Estimated HZ vaccine coverage is 19.5% in adults aged ≥60 years, which is lower than the Healthy People 2020 target of 30%. Providers should identify every opportunity for HZ vaccination to assure that older adults are protected from HZ, a vaccine-preventable disease.